Sally A. El‑Zahaby

Prof. Dr. Sally A. El‑Zahaby


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAAbdulaziz M. Al-Mahallawi
Abdulaziz M. Al-Mahallawi
SESally A. El‑Zahaby
Sally A. El‑Zahaby
SESally A. El-Zahaby
Sally A. El-Zahaby

1 December 2014 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
SESally A. El‑Zahaby
Sally A. El‑Zahaby
AKAbeer Ahmed Kassem
Abeer Ahmed Kassem
AEAmal H El-Kamel
Amal H El-Kamel
Gastroretentive levofloxacin (LVF) floating mini-tablets for the eradication of Helicobacter pylori (H. pylori) were prepared using the matrix forming polymer hydroxypropyl methylcellulose (HPMC K100M), alone or with Carbopol 940P in different ratios by wet granulation technique. Buoyancy of mini-tablets was achieved by an addition of an effervescent mixture consisting of sodium bicarbonate and anhydrous citric acid to some formulations. The prepared mini-tablets were evaluated for weight variation, thickness, friability, hardness, drug content, in vitro buoyancy, water uptake and in vitro release. The optimized formula was subjected to further studies: FT-IR, DSC analysis and in vivo examination in healthy volunteers. The prepared mini-tablets exhibited satisfactory physicochemical characteristics. Incorporation of gas-generating agent improved the floating parameters. HPMC K100M mini-tablet formulation (F1) offered the best controlled drug release (>8 h) along with floating lag time 24 h. The obtained DSC thermograms and FT-IR charts indicated that there is no positive evidence for the interaction between LVF and ingredients of the optimized formula. The in vivo test confirmed the success of the optimized formula F1 in being retained in the stomach of the volunteers for more than 4 h. LVF floating mini-tablets based on HPMC K100M is a promising formulation for eradication of H. pylori.

1 January 2021 in Drug Delivery
Verified
Journal Article
Open access
MWMing Ming Wen
Ming Ming Wen
IAIbrahim A. Abdelwahab
Ibrahim A. Abdelwahab
RARania G. Aly
Rania G. Aly
SESally A. El‑Zahaby
Sally A. El‑Zahaby
Burn wound is usually associated by antibiotic-resistant Pseudomonas aeruginosa infection that worsens and complicates its management. An effective approach is to use natural antibiotics such as cinnamon oil as a powerful alternative. This study aims to investigate topical nanostructured lipid carrier (NLC) gel loaded cinnamon oil for Pseudomonas aeruginosa wound infection. A 24 full factorial design was performed to optimize the formulation with particle size 108.48 ± 6.35 nm, zeta potential −37.36 ± 4.01 mV, and EE% 95.39 ± 0.82%. FTIR analysis revealed no excipient interaction. Poloxamer 407 in a concentration 20% w/w NLC gel was prepared for topical application. Drug release exhibited an initial burst release in the first five hours, followed by a slow, sustained release of up to five days. NLC-cinnamon gel has a significant ability to control the drug release with the lowest minimum inhibitory concentration again P. aeruginosa compared to other formulations (p < .05). In vivo study also showed NLC-cinnamon gel effectively healed the infected burned wound after a six-day treatment course with better antibacterial efficacy in burned animal models. Histological examination ensured the tolerability of NLC-cinnamon gel. The results suggest that nanoparticle-based cinnamon oil gel is a promising natural product against antibiotic-resistant strains of P. aeruginosa in wound infection.

1 April 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SESally A. El‑Zahaby
Sally A. El‑Zahaby
AKAbeer Ahmed Kassem
Abeer Ahmed Kassem
AEAmal H El-Kamel
Amal H El-Kamel

6 September 2021 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
DGDoaa A. Ghareeb
Doaa A. Ghareeb
SSSamar R. Saleh
Samar R. Saleh
MSMohamed G. Seadawy
Mohamed G. Seadawy
MNMohammed S. Nofal
Mohammed S. Nofal
SAShaymaa A. Abdulmalek
Shaymaa A. Abdulmalek
MDMaha Adel El Demellawy
Maha Adel El Demellawy

12 March 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MSMona G. Sakr
Mona G. Sakr
SESally A. El‑Zahaby
Sally A. El‑Zahaby
AAAbdulaziz Al-mahallawi
Abdulaziz Al-mahallawi
DGDalia M. Ghorab
Dalia M. Ghorab